Credit: AP Liao, et al. / public library of science The paper: M.J. Evans, et al., "Claudin1 is a hepatitis C virus co-receptor required for a late step in entry," Nature, 446:801-5, 2007. (Cited in 81 papers) The finding: In attempts to find out why hepatitis C virus (HCV) would not infect any cell type except liver, Matthew Evans at" /> Credit: AP Liao, et al. / public library of science The paper: M.J. Evans, et al., "Claudin1 is a hepatitis C virus co-receptor required for a late step in entry," Nature, 446:801-5, 2007. (Cited in 81 papers) The finding: In attempts to find out why hepatitis C virus (HCV) would not infect any cell type except liver, Matthew Evans at" />
Advertisement
Salesforce
Salesforce

Junction function

Credit: AP Liao, et al. / public library of science" /> Credit: AP Liao, et al. / public library of science The paper: M.J. Evans, et al., "Claudin1 is a hepatitis C virus co-receptor required for a late step in entry," Nature, 446:801-5, 2007. (Cited in 81 papers) The finding: In attempts to find out why hepatitis C virus (HCV) would not infect any cell type except liver, Matthew Evans at

By | February 1, 2009

<figcaption> Credit: AP Liao, et al. / public library of science</figcaption>
Credit: AP Liao, et al. / public library of science

The paper:

M.J. Evans, et al., "Claudin1 is a hepatitis C virus co-receptor required for a late step in entry," Nature, 446:801-5, 2007. (Cited in 81 papers)

The finding:

In attempts to find out why hepatitis C virus (HCV) would not infect any cell type except liver, Matthew Evans at The Rockefeller University and colleagues expressed liver proteins in kidney cells and screened for HCV infection. The researchers found claudin-1, a tight junction protein which binds epithelial cells together at their sides, allowed the virus to infect a non-liver cell.

The impact:

Current antiviral drugs that target some aspect of viral replication are usually not effective for very long; "viruses realize ways to sneak around" and resist the drug, says Evans. Blocking an entry protein, like claudin-1, on the host would strengthen any combination therapy for hepatitis C, a leading cause of liver failure.

The big picture:

The finding adds to a growing body of literature that implicates tight junction proteins in viral entry, says Alan Yu, a nephrologist at the University of Southern California Keck School of Medicine. The viruses essentially are a ligand for relaxing cellular tight junctions-a finding that could be useful in drug delivery technology, says Yu.

The numbers:
claudin-1 inserted: Kidney cell infection increased 300 fold
claudin-1 silenced: Liver cell infection inhibited 50 fold
Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
RayBiotech
RayBiotech

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Horizon Discovery
Horizon Discovery
Advertisement
The Scientist
The Scientist
Life Technologies